Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175719 | 0.90 | NPBWR1 (0.37) | HSD11B1SMN1; SMN2LMNANPSR1NPBWR1 | |
| SCHEMBL4175723 | 0.90 | NPBWR1 (0.37) | HSD11B1SMN1; SMN2LMNANPSR1NPBWR1 | |
| SCHEMBL8169147 | 0.89 | HSD11B1 (0.36) | HSD11B1SMN1; SMN2LMNANPSR1MAPT | |
| SCHEMBL29531652 | 0.88 | SMN1; SMN2 (0.40) | HSD11B1SMN1; SMN2LMNANPSR1MAPT | |
| SCHEMBL2211524 | 0.87 | SMN1; SMN2 (0.37) | HSD11B1SMN1; SMN2LMNANPSR1MAPT | |
| SCHEMBL4179397 | 0.83 | HSD11B1 (0.39) | HSD11B1SMN1; SMN2LMNANPSR1MAPT | |
| SCHEMBL4179392 | 0.83 | HSD11B1 (0.39) | HSD11B1SMN1; SMN2LMNANPSR1MAPT | |
| SCHEMBL4179389 | 0.83 | HSD11B1 (0.39) | HSD11B1SMN1; SMN2LMNANPSR1MAPT | |
| SCHEMBL4184940 | 0.82 | NPSR1 (0.39) | HSD11B1SMN1; SMN2LMNANPSR1MAPT | |
| SCHEMBL5963959 | 0.81 | HSD11B1 (0.39) | HSD11B1SMN1; SMN2LMNANPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | HSD11B1 1690/4885SMN1; SMN2 1918/4885LMNA 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.